PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- PMID: 28878676
- PMCID: PMC5572324
- DOI: 10.3389/fphar.2017.00561
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Abstract
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to maintain the imbalance between immune surveillance and cancer cell proliferation. Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction. These checkpoint blockers are rapidly becoming a highly promising cancer therapeutic approach that yields remarkable antitumor responses with limited side effects. In recent times, more than four check point antibody inhibitors have been commercialized for targeting PD-1, PDL-1, and CTLA-4. Despite the huge success and efficacy of the anti-PD therapy response, it is limited to specific types of cancers, which attributes to the insufficient and heterogeneous expression of PD-1 in the tumor microenvironment. Herein, we review the current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment. We also review the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer.
Keywords: PD-1/PDL-1 mechanism; atezolizumab; challenges and new approach; combination immune therapy; immune resistance; immunotherapy; nivolumab; tumor stroma role in PD-1/PD-L1.
Figures
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Eur Urol. 2015. PMID: 25824720 Review.
-
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review.
-
Current studies of immunotherapy in head and neck cancer.Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29. Clin Otolaryngol. 2018. PMID: 28464441 Review.
-
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.Front Oncol. 2020 Feb 28;10:268. doi: 10.3389/fonc.2020.00268. eCollection 2020. Front Oncol. 2020. PMID: 32185135 Free PMC article. Review.
Cited by
-
Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study.Sci Rep. 2024 Oct 23;14(1):25030. doi: 10.1038/s41598-024-76296-y. Sci Rep. 2024. PMID: 39443515 Free PMC article.
-
Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Curr Mol Med. 2024;24(12):1461-1469. doi: 10.2174/0115665240266906231024111920. Curr Mol Med. 2024. PMID: 39420726 Review.
-
Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus.Cancers (Basel). 2024 Sep 24;16(19):3248. doi: 10.3390/cancers16193248. Cancers (Basel). 2024. PMID: 39409870 Free PMC article.
-
The Comparative Oncology of Canine Malignant Melanoma in Targeted Therapy: A Systematic Review of In Vitro Experiments and Animal Model Reports.Int J Mol Sci. 2024 Sep 26;25(19):10387. doi: 10.3390/ijms251910387. Int J Mol Sci. 2024. PMID: 39408717 Free PMC article. Review.
-
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.Clin Transl Med. 2024 Oct;14(10):e70048. doi: 10.1002/ctm2.70048. Clin Transl Med. 2024. PMID: 39390760 Free PMC article.
References
-
- Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., et al. . (1996). Expression of the PD-1 antigen on the surface of stimulated mouse, T and B lymphocytes. Int. Immunol. 8, 765–772. - PubMed
-
- Antonia S., Goldberg S. B., Balmanoukian A., Chaft J. E., Sanborn R. E., Gupta A., et al. . (2016). Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1B study. Lancet Oncol. 17, 299–308. 10.1016/S1470-2045(15)00544-6 - DOI - PMC - PubMed
-
- Atkins M. B., Kudchadkar R. R., Sznol M., McDermott D. F., Lotem M., Schachter J., et al. (2014). Phase 2, Multicenter, Safety and Efficacy Study of Pidilizumab in Patients with Metastatic Melanoma. American Society of Clinical Oncology.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials